Breast cancer is the most common cancer in Canada, predominantly affecting women, with more than 29,000 diagnoses in 2023. It’s complexity is underscored by more than 50 unique types, making each diagnosis distinct and challenging to treat, according to Kimberly Carson, chief executive officer of Breast Cancer Canada, during a session supported by AstraZeneca Canada […]
Private drug plans play a pivotal role in ensuring faster and broader access to medications for 27 million Canadians, said Joe Farago, executive director of private payers and investment at Innovative Medicines Canada, during Benefits Canada’s 2024 Face to Face Drug Plan Management Forum. The federal government’s new pharmacare plan is designed as a universal, […]
Plan sponsors are facing a chronic disease “tsunami” that is leading to higher benefits and drug plan spend and increasing disability claims. But the three root causes of this growing problem — undiagnosed health issues, the availability of primary and preventative health care and challenges navigating the health-care system — are issues plan sponsors are […]
Innovative Medicines Canada is calling on the federal government to introduce amendments to Bill C-64 that clarify the impact on all aspects of Canadians’ drug coverage. In a press release, the association urged the feds to ensure its new pharmacare program doesn’t disrupt existing coverage for the 27 million Canadians who are insured under a […]
Plan sponsors worried about the expense and sustainability of their drug plan might initially embrace a pharmacare plan, hoping to shift drug costs to a new program funded by provincial and federal governments. However, this may not be the solution it seems. A single-payer universal pharmacare system might limit medication access for individuals with employer-sponsored benefits […]
Although mental health is approached differently in workplaces around the globe, most multinational employers want to ensure a continuity of care and maintain a similar experience for all employees, while respecting local cultural and legal considerations. For Scotiabank, these considerations include focusing on what types of support are needed, what the employee experience is going […]
In the year ahead, the Canadian Life and Health Insurance Association will continue its advocacy efforts to ensure the federal government’s proposed pharmacare plan extends coverage for those who lack benefits without disrupting workplace benefits that millions of working Canadians rely on, says Stephen Frank, the association’s president and chief executive officer. The right approach to […]
With the new Canadian Dental Care Plan rolling out, it’s critical that it doesn’t displace existing employer-sponsored dental coverage, says Stephen Frank, president and chief executive officer of the Canadian Life and Health Insurance Association. He believes a tax credit would be an optimal solution that would go a long way towards encouraging employers not […]
The growth of gene and cell therapies are raising significant questions among private payers about who bears the responsibility for the costs of these treatments, says Tim Clarke, president at TC Health Consulting Inc. “One issue is whether this is going to be paid for by public health or if it’s an employer health issue. […]
With Yukon implementing a transitioning policy on April 3 to expand the use of biosimilar medicines in its public drug plan, it’s important for benefits plan sponsors that create a similar policy for their workplace plans to be clear in their communication and education with employees. “It’s never easy to switch a medication, especially when […]